LivaNova (LIVN) Research & Development (2014 - 2026)
LivaNova (LIVN) posted Research & Development of $58.7 million for Q1 2026, up 12.61% sequentially from $52.1 million in Q4 2025, and up 54.95% YoY from $37.9 million in Q1 2025.
LivaNova (LIVN) Research & Development (2014 - 2026) Analysis & Trends
LivaNova has reported Research & Development for 13 years, with the latest figure at $58.7 million in Q1 2026.
- Quarterly Research & Development rose 54.95% year-over-year to $58.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $206.6 million (up 18.23% YoY) and the FY2025 annual result came in at $185.8 million, up 1.78% from the prior year.
- Research & Development rose to $58.7 million in Q1 2026 per LIVN's latest filing, from $52.1 million in the prior quarter.
- Over five years, Research & Development peaked at $58.7 million in Q1 2026 and troughed at $34.2 million in Q2 2022.
- A 5-year average of $45.7 million and a median of $46.2 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2026: Research & Development slumped 34.87% in 2022, then jumped 54.95% in 2026.
- Over 5 years, Research & Development stood at $44.9 million in 2022, then gained by 2.74% to $46.2 million in 2023, then retreated by 6.19% to $43.3 million in 2024, then gained by 20.35% to $52.1 million in 2025, then increased by 12.61% to $58.7 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $58.7 million, $52.1 million, and $48.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.18 Bn | 194.58 Bn | 7.27 Bn | 892.00 Mn |
| 2 | Stryker | 129.87 Bn | 126.39 Bn | 4.50 Bn | 434.00 Mn |
| 3 | Medtronic | 120.25 Bn | 111.03 Bn | 6.41 Bn | 671.00 Mn |
| 4 | Boston Scientific | 73.97 Bn | 73.43 Bn | 3.85 Bn | 554.00 Mn |
| 5 | Edwards Lifesciences | 52.73 Bn | 48.48 Bn | 1.35 Bn | 278.90 Mn |
| 6 | Dexcom | 34.66 Bn | 32.71 Bn | 830.00 Mn | 153.00 Mn |
| 7 | GE HealthCare Technologies | 34.17 Bn | 32.06 Bn | 2.18 Bn | 323.00 Mn |
| 8 | Koninklijke Philips | 26.51 Bn | 23.19 Bn | 4.55 Bn | -562.58 Mn |
| 9 | Steris | 23.24 Bn | 22.75 Bn | 684.20 Mn | 28.60 Mn |
| 10 | LivaNova | 4.36 Bn | 3.84 Bn | 273.67 Mn | 53.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.66 Mn |
| Mar 31, 2026 | 58.70 Mn |
| Dec 31, 2025 | 52.12 Mn |
| Sep 30, 2025 | 48.58 Mn |
| Jun 30, 2025 | 47.19 Mn |
| Mar 31, 2025 | 37.88 Mn |
| Dec 31, 2024 | 43.31 Mn |
| Sep 30, 2024 | 48.81 Mn |
| Jun 30, 2024 | 44.74 Mn |
| Mar 31, 2024 | 45.66 Mn |
| Dec 31, 2023 | 46.17 Mn |
| Sep 30, 2023 | 46.54 Mn |
| Jun 30, 2023 | 51.12 Mn |
| Mar 31, 2023 | 49.99 Mn |
| Dec 31, 2022 | 44.93 Mn |
| Sep 30, 2022 | 35.73 Mn |
| Jun 30, 2022 | 34.23 Mn |
| Mar 31, 2022 | 40.92 Mn |
| Dec 31, 2021 | 44.10 Mn |
| Sep 30, 2021 | 42.13 Mn |